Pfizer forecasts higher COVID-19 vaccine, pill sales in 2022, but analysts expected more

Pfizer raised the guidance on its anticipated vaccine and COVID-19 antiviral pill Paxlovid on Tuesday, but not as high as analysts had been expecting.

Latest articles

Related articles